7
42 J ournal of Medicinal Chemistry, 2004, Vol. 47, No. 3
T o¨ mb o¨ ly et al.
(
14) Fiori, S.; Renner, C.; Cramer, J .; Pegoraro, S.; Moroder, L.
Preferred conformation of endomorphin-1 in aqueous and mem-
brane-mimetic environments. J . Mol. Biol. 1999, 291, 163-175.
15) Paterlini, M. G.; Avitabile, F.; Ostrowski, B. G.; Ferguson, D.
M.; Portoghese, P. S. Stereochemical requirements for receptor
recognition of the mu-opioid peptide endomorphin-1. Biophys.
J . 2000, 78, 590-599.
16) In, Y.; Minoura, K.; Ohishi, H.; Minakata, H.; Kamigauchi, M.;
Sugiura, M.; Ishida, T. Conformational comparison of µ-selective
endomorphin-2 with its C-terminal free acid in DMSO solution,
by 1H NMR spectroscopy and molecular modeling calculation.
J . Pept. Res. 2001, 58, 399-412.
(37) Erspamer, G. F.; Severini, C. Guinea-pig ileum (GPI) and mouse
vas deferens (MVD) preparations in the discovery, discrimination
and parallel bioassay of opioid peptides. Pharmacol. Res. 1992,
26, 109-121.
(38) Al-Khrasani, M.; Orosz, Gy.; Kocsis, L.; Farkas, V.; Magyar, A.;
Lengyel, I.; Benyhe, S.; Borsodi, A.; R o´ nai, A. Z. Receptor
constants for endomorphin-1 and endomorphin-1-ol indicate
differences in efficacy and receptor occupancy. Eur. J . Pharma-
col. 2001, 421, 61-67.
(39) W u¨ thrich, K. NMR of proteins and nucleic acids; Wiley: New
York, 1986.
(40) Nardi, F.; Kemmink, J .; Sattler, M.; Wade, R. C. The cisproline-
(i-1)-aromatic(i) interaction: Folding of the Ala-cis-Pro-Tyr
peptide characterized by NMR and theoretical approaches. J .
Biomol. NMR 2000, 17, 63-77.
(
(
(
17) Lengyel, I.; Orosz, Gy.; Biyashev, D.; Kocsis, L.; Al Khrasani,
M.; R o´ nai, A. Z.; T o¨ mb o¨ ly, Cs.; F u¨ rst, Z.; T o´ th, G.; Borsodi, A.
Side chain modifications change the binding and agonist proper-
ties of endomorphin-2. Biochem. Biophys. Res. Commun. 2002,
(41) Wu, W. J .; Raleigh, D. P. Local control of peptide conformation:
Stabilization of cis proline peptide bonds by aromatic proline
interactions. Biopolymers 1998, 45, 381-394.
2
90, 153-161.
(
(
(
18) P e´ ter, A.; T o´ th, G.; T o¨ mb o¨ ly, Cs.; Laus, G.; Tourw e´ , D. Liquid
chromatographic study of the enzymatic degradation of endo-
morphins, with identification by electrospray ionization mass
spectrometry. J . Chromatogr. A. 1999, 846, 39-48.
42) Poznanski, J .; Ejchart, A.; Wierzchowski, K. L.; Ciurak, M. 1H
(
13
and C NMR investigations on cis-transisomerization of proline
peptide bonds and conformation of aromatic side chains in
19) Eguchi, M.; Shen, R. Y.; Shea, J . P.; Lee, M. S.; Kahn, M. Design,
synthesis, and evaluation of opioid analogues with nonpeptidic
â-turn scaffold: enkephalin and endomorphin mimetics. J . Med.
Chem. 2002, 45, 1395-1398.
n
H-Trp-(Pro) -Tyr-OH peptides. Biopolymers 1993, 33, 781-795.
(
43) Bystrov, V. F. Spin-spin coupling and the conformational states
of peptide systems. Prog. NMR Spectrosc. 1976, 10, 41-81.
44) Cung, M. T.; Marraud, M. Conformational dependence of the
(
20) Keller, M.; Boissard, C.; Patiny, L.; Chung, N. N.; Lemieux, C.;
Mutter, M.; Schiller, P. W. Pseudoproline-containing analogues
of morphiceptin and endomorphin-2: evidence for a cis Tyr-Pro
amide bond in the bioactive conformation. J . Med. Chem. 2001,
R â
vicinal proton coupling constant for the C -C bond in peptides.
Biopolymers 1982, 21, 953-967.
45) Kessler, H.; Griesinger, C.; Wagner, K. Peptide conformations.
(
4
2. Conformation of side chains in peptides using heteronuclear
4
4, 3896-3903.
21) Chang, K. J .; Lillian, A.; Hazum, E.; Cuatrecasas, P.; Chang, J .
K. Morphiceptin (H-Tyr-Pro-Phe-Pro-NH ): a potent and specific
coupling constants obtained by two-dimensional NMR spectros-
copy. J . Am. Chem. Soc. 1987, 109, 6927-6933.
(
2
(
46) Mosberg, H. I.; Omnaas, J . R.; Lomize, A.; Heyl, D. L.; Nordan,
I.; Mousigian, C.; Davis, P.; Porreca, F. Development of a model
for the delta opioid receptor pharmacophore. 2. Conformationally
agonist for morphine (mu) receptors. Science 1981, 212, 75-77.
22) Chang, K. J .; Wei, E. T.; Killian, A.; Chang, J . K. Potent
morphiceptin analogues: structure activity relationships and
morphine-like activities. J . Pharmacol. Exp. Ther. 1983, 227,
(
3
restricted Phe replacements in the cyclic delta receptor selective
tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]-OH (J OM-13). J . Med.
Chem. 1994, 37, 4384-4391.
4
03-408.
(
23) EÄ rchegyi, J .; Kastin, A. J .; Zadina, J . E. Isolation of a novel
tetrapeptide with opiate and antiopiate activity from human
brain cortex: Tyr-Pro-Trp-Gly-NH2 (Tyr-W-MIF-1). Peptides
(
47) Mosberg, H. I. Complementarity of delta opioid ligand pharma-
cophore and receptor models. Biopolymers 1999, 51, 426-439.
48) Przewlocki, R.; Labuz, D.; Mika, J .; Przewlocka, B.; T o¨ mb o¨ ly,
Cs.; T o´ th, G. Pain inhibition by endomorphins. Ann. N. Y. Acad.
Sci. 1999, 897, 154-164.
(
1
992, 13, 623-631.
(
24) Hackler, L.; Kastin, A. J .; EÄ rchegyi, J .; Zadina, J . E. Isolation
of Tyr-W-MIF-1 from bovine hypothalami. Neuropeptides 1993,
(
49) Nevin, S. T.; Kabasakal, L.; O¨ tv o¨ s, F.; T o´ th, G.; Borsodi, A.
2
4, 159-164.
Binding characteristics of the novel highly selective delta
(
25) Okada, Y.; Fukumizu, A.; Takahashi, M.; Shimizu, Y.; Tsuda,
Y.; Yokoi, T.; Bryant, S. D.; Lazarus, L. H. Synthesis of
stereoisomeric analogues of endomorphin-2, H-Tyr-Pro-Phe-Phe-
3
5,6
agonist, [ H]IIe deltorphin II. Neuropeptides 1994, 26, 261-
65.
2
(
(
(
50) Bax, A.; Davis, D. G. MLEV-17-Based two-dimensional homo-
NH
and solution conformation. Biochem. Biophys. Res. Commun.
000, 276, 7-11.
2
, and examination of their opioid receptor binding activities
nuclear magnetization transfer spectroscopy. J . Magn. Res. 2003,
6
5, 355-360.
2
51) K o¨ v e´ r, K. E.; Uhrin, D.; Hruby, V. J . Gradient- and sensitivity-
(
26) Cardillo, G.; Gentilucci, L.; Melchiorre, P.; Spampinato, S.
Synthesis and binding activity of endomorphin-1 analogues
containing beta-amino acids. Bioorg. Med. Chem. Lett. 2000, 10,
enhanced TOCSY experiments. J . Magn. Res. 1998, 130, 162-
1
68.
52) Bothner-By, A. A.; Stephens, R. L.; Lee, J . M. Structure
determination of a tetrasaccharide: transient nuclear Over-
hauser effects in the rotating frame. J . Am. Chem. Soc. 1984,
2
755-2758.
(
27) Cardillo, G.; Gentilucci, L.; Qasem, A. R.; Sgarzi, F.; Spampinato,
S. Endomorphin-1 analogues containing beta-proline are mu-
opioid receptor agonists and display enhanced enzymatic hy-
drolysis resistance. J . Med. Chem. 2002, 45, 2571-2578.
28) Yamazaki, T.; Ro, S.; Goodman, M.; Chung, N. N.; Schiller, P.
W. A topochemical approach to explain morphiceptin bioactivity.
J . Med. Chem. 1993, 36, 708-719.
1
06, 811-813.
(
53) Bax, A.; Davis, D. G. Practical aspects of two-dimensional
transverse NOE spectroscopy. J . Magn. Res. 1985, 63, 207-213.
54) Palmer III, A. G.; Cavanagh, J .; Wright, P. E.; Rance, M.
Sensitivity improvement in proton-detected two-dimensional
heteronuclear correlation NMR spectroscopy. J . Magn. Res.
(
(
(
29) Szatm a´ ri, I.; Biyashev, D.; T o¨ mb o¨ ly, Cs.; T o´ th, G.; M a´ csai, M.;
Szab o´ , Gy.; Borsodi, A.; Lengyel, I. Influence of degradation on
binding properties and biological activity of endomorphin-1.
Biochem. Biophys. Res. Commun. 2001, 284, 771-776.
30) Hruby, V. J .; Al-Obeidi, F.; Kazmierski, W. Emerging approaches
in the molecular design of receptor-selective peptide ligands:
conformational, topographical and dynamic considerations. Bio-
chem. J . 1990, 268, 249-262.
1
991, 93, 151-170.
55) Uhrin, D.; Batta, G.; Hruby, V. J .; Barlow, P. N.; K o¨ v e´ r, K. E.
Sensitivity- and gradient-enhanced hetero (w ) half- filtered
(
1
TOCSY experiment for measuring long-range coupling con-
stants. J . Magn. Res. 1998, 130, 155-161.
56) Kozminski, W.; Nanz, D. HECADE: HMQC- and HSQC-based
(
(
2
D NMR experiments for accurate and sensitive determination
of heteronuclear coupling constants from TOCSY-type cross-
(
31) Hruby, V. J .; T o´ th, G.; Gehrig, C. A.; Kao, L. F.; Knapp, R.; Lui,
G. K.; Yamamura, H. I.; Kramer, T. H.; Davis, P.; Burks, T. F.
peaks. J . Magn. Res. 1997, 124, 383-392.
2
5
(57) Kataoka, Y.; Seto, Y.; Yamamoto, M.; Yamada, T.; Kuwata, S.;
Watanabe, H. Studies of unusual amino acids and their peptides.
VI. The synthesis and the optical resolutions of â-methylphe-
nylalanine and its dipeptide present in bottromycin. Bull. Chem.
Soc. J pn. 1976, 49, 1081-1084.
Topographically designed analogues of [D-Pen ,D-Pen ]enkephalin.
J . Med. Chem. 1991, 34, 1823-1830.
(
(
(
32) Hruby, V. J .; Li, G.; Haskell-Luevano, C.; Shenderovich, M.
Design of peptides, proteins, and peptidomimetics in chi space.
Biopolymers 1997, 43, 219-266.
33) T o´ th, G.; Lebl, M.; Hruby, V. J . Chiral TLC separation of
modified phenylalanine and tyrosine derivatives. J . Chromatogr.
(58) Simon, J .; Benyhe, S.; Abutidze, K.; Borsodi, A.; Sz _u cs, M.; T o´ th,
G.; Wollemann, M. Kinetics and physical parameters of rat brain
opioid receptors solubilized by digitonin and CHAPS. J . Neuro-
chem. 1986, 46, 695-701.
1
990, 504, 450-455.
34) T o¨ mb o¨ ly, Cs.; Dixit, R.; Lengyel, I.; Borsodi, A.; T o´ th, G.
Preparation of specifically tritiated endomorphins. J . Labelled
Compds. Radiopharm. 2001, 44, 355-363.
(59) Bradford, M. M. A rapid and sensitive method for the quanti-
tation of microgram quantities of protein utilizing the principle
of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
(60) Traynor, J . R.; Nahorski, S. R. Modulation by µ-opioid agonists
(
35) T o¨ mb o¨ ly, Cs.; P e´ ter, A.; T o´ th, G. In vitro quantitative study of
the degradation of endomorphins. Peptides 2002, 23, 1573.
36) Goldstein, A.; Naidu, A. Multiple opioid receptors: ligand
selectivity profiles and binding site signatures. Mol. Pharmacol.
3
5
(
of guanosine-5′-O-(γ-[ S]thio)triphosphate binding to membranes
from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol.
1995, 47, 848-854.
1
989, 36, 265-272.